We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Rexulti Lands Priority Review for Alzheimer’s Agitation Drug
Rexulti Lands Priority Review for Alzheimer’s Agitation Drug
Otsuka and developmental partner Lundbeck have snagged FDA priority review of their supplemental new drug application (sNDA) for Rexulti (brexpiprazole) as a treatment for agitation in people with Alzheimer’s disease.